Table 3.

List of novel respiratory therapies approved by the US Food and Drug Administration since 2011

Year	Name	Active Ingredient	Therapeutic Application	Class	Manufacturer
2019
	Trikafta	Elexacaftor/ ivacaftor/tezacaftor	Cystic fibrosis	CFTR channel potentiator	Vertex Pharmaceuticals
2018
	Dupixent	Dupilumab	Asthma	IL4-Rα mAb	Regeneron Pharmaceuticals
2017
	Fasenra	Benralizumab	Asthma	IL5-Rα mAb	Astra Zeneca Pharmaceuticals
2016
	Cinqair	Reslizumab	Asthma	Humanized anti-IL5 mAb	Teva Pharmaceuticals
2015
	Tagrisso	Osimertinib	Cancer	EGFR-blocking therapy	Astra Zeneca Pharmaceuticals
	Nucala	Mepolizumab	Asthma	Humanized anti-IL5 mAb	GlaxoSmithKline
	Okambi	Lumacaftor ivacaftor	Cystic fibrosis	CFTR channel potentiator	Vertex Pharmaceuticals
2014
	Esbriet	Pirfenidone	IPF	Multiple pathways	InterMune
	Ofev	Nintedanib	IPF	Kinase inhibitor	Boehringer Ingelheim Pharmaceuticals
2013
	Anoro Ellipta	Umeclidinium vilanterol	COPD	Anticholinergic, long-acting β2-adrenergic agonist	GlaxoSmithKline
	Breo Ellipta	Fluticasone fuorate/ vilanterol	COPD	Corticosteroid, long-acting β2-adrenergic agonist	GlaxoSmithKline
2012
	Situro	Bedaquiline	TB	Antibiotic	Janssen Therapeutics
	Tudorza Pressair	Aclidinium bromide	COPD	Long-acting antimuscarinic agent	Forest Pharmaceuticals
2011
	Arcapta Neohaler	Indacaterol	COPD	Long-acting β2-adrenergic agonist	Novartis Pharmaceuticals
	Daliresp	Roflumilast	COPD	Phosphodiesterase type 4 inhibitor	Forest Pharmaceuticals

COPD, chronic obstructive pulmonary disease; EGFR, epidermal growth factor receptor; IPF, idiopathic pulmonary fibrosis; TB, tuberculosis.